New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareThymulin vs FOXO4-DRI

Thymulin vs FOXO4-DRI

Side-by-side comparison of key properties, dosing, and research.

Immune Support
Thymulin
Anti-Aging & Longevity
FOXO4-DRI
Summary
Thymulin is a nonapeptide hormone produced exclusively by the thymic epithelium. It requires zinc for biological activity and plays a critical role in T-lymphocyte maturation, differentiation, and immune regulation. Thymulin levels decline dramatically with age, contributing to immunosenescence.
FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
Half-Life
~30 minutes active half-life
Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
Admin Route
SubQ
Subcutaneous, Intraperitoneal (research)
Research
Typical Dose
20-30 mcg
5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
Frequency
10 days per month (Khavinson protocol)
3 consecutive days per cycle
Key Benefits
  • Enhances T-cell maturation and differentiation
  • Boosts NK cell cytotoxic activity
  • Reduces inflammatory cytokine production (TNF-α, IL-1)
  • Anti-nociceptive (pain-reducing) properties
  • Restores age-related immune decline
  • Anti-inflammatory via serotonin pathway modulation
  • Selectively clears senescent cells (senolytics)
  • Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
  • Demonstrated restoration of physical fitness in aged mice
  • May improve healthspan and reduce age-related tissue dysfunction
  • Potential for treatment of age-related pathologies driven by cellular senescence
  • Does not affect healthy non-senescent cells at therapeutic doses
Side Effects
  • Injection site reactions
  • Mild fatigue initially as immune system activates
  • Limited human data; largely preclinical evidence
  • Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
  • Weight loss observed at high doses in rodent studies
  • Unknown long-term safety profile in humans
Stacks With